Mesa Laboratories (NASDAQ:MLAB) Shares Cross Above Fifty Day Moving Average - Should You Sell?

Key Points

• Mesa Laboratories shares crossed above their 50-day moving average, trading at $136.91 versus a $128.45 average. Jefferies raised its price target to $150 and maintained a Buy rating, while the overall analyst consensus remains Hold.
• Fiscal Q2 revenue rose 2.6% to $62.3 million, and adjusted EBITDA increased 21.1% to $17.3 million; however, diluted EPS missed the cited consensus, and revenue declined in Biopharmaceutical Development and Clinical Genomics.
• The company forecast fiscal 2027 adjusted EBITDA of $66 million–$68 million, authorized up to $40 million in share repurchases, and repaid $11.4 million of debt, reducing its net leverage ratio to 1.75.

Mesa Laboratories, Inc. (NASDAQ:MLAB - Get Free Report) crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $128.45 and traded as high as $138.08. Mesa Laboratories shares last traded at $136.91, with a volume of 234,179 shares changing hands.

More Mesa Laboratories News

Here are the key news stories impacting Mesa Laboratories this week:

• Positive Sentiment: Jefferies raised its price target to $150 from $125 and maintained a Buy rating, implying about 9.6% upside from the cited share price. Analyst price target report
• Positive Sentiment: Fiscal Q2 adjusted EBITDA rose 21.1% to $17.3 million, operating income increased 77.6%, and net income grew 75.3%. Mesa also repaid $11.4 million of debt, lowering its net leverage ratio to 1.75. Q2 results and guidance
• Positive Sentiment: The company authorized a new share-repurchase program of up to $40 million, which may support demand for shares, though repurchases are discretionary. Fiscal 2027 adjusted EBITDA guidance of $66 million–$68 million also forecasts 5%–8% growth. Company announcement
• Neutral Sentiment: Revenue increased 2.6% to $62.3 million, slightly above consensus, while the $250 million–$255 million full-year revenue forecast broadly brackets the $254.5 million consensus estimate. Company announcement
• Neutral Sentiment: A short-interest report lists 0 shares sold short, so it does not indicate meaningful short-covering potential.
• Negative Sentiment: Reported diluted EPS of $0.75 missed the cited analyst consensus of $2.29. Biopharmaceutical Development revenue fell 8.2%, and Clinical Genomics revenue fell 8.8%; Mesa expects Clinical Genomics sales to decline further in the second half and into fiscal 2028. Q2 results and guidance

Analyst Ratings Changes

Several research firms recently weighed in on MLAB. Wells Fargo & Company upped their price target on Mesa Laboratories from $94.00 to $110.00 and gave the stock an "equal weight" rating in a research note on Friday, August 14th. Jefferies Financial Group lifted their price objective on Mesa Laboratories from $125.00 to $150.00 and gave the company a "buy" rating in a research note on Tuesday. Weiss Ratings raised Mesa Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a report on Thursday, October 8th. Finally, Wall Street Zen raised Mesa Laboratories from a "buy" rating to a "strong-buy" rating in a research note on Saturday, October 3rd. One equities research analyst has rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Mesa Laboratories presently has an average rating of "Hold" and a consensus target price of $130.00.

Mesa Laboratories Price Performance

The company has a quick ratio of 1.32, a current ratio of 1.79 and a debt-to-equity ratio of 0.73. The firm has a market capitalization of $766.15 million, a PE ratio of 120.10 and a beta of 1.08. The firm's fifty day simple moving average is $128.45 and its 200-day simple moving average is $105.41.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The medical instruments supplier reported $2.68 EPS for the quarter. Mesa Laboratories had a net margin of 2.65% and a return on equity of 23.00%. The firm had revenue of $60.14 million for the quarter.

Mesa Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 15th. Stockholders of record on Monday, November 30th will be paid a $0.16 dividend. The ex-dividend date is Monday, November 30th. This represents a $0.64 annualized dividend and a dividend yield of 0.5%. Mesa Laboratories's payout ratio is currently 56.14%.

Insider Transactions at Mesa Laboratories

In other Mesa Laboratories news, CEO Siddhartha Kadia acquired 7,093 shares of the company's stock in a transaction that occurred on Thursday, August 13th. The shares were bought at an average cost of $112.80 per share, with a total value of $800,090.40. Following the completion of the transaction, the chief executive officer directly owned 7,093 shares of the company's stock, valued at approximately $800,090.40. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director R Tripeny acquired 900 shares of Mesa Laboratories stock in a transaction that occurred on Thursday, August 13th. The stock was acquired at an average price of $113.69 per share, with a total value of $102,321.00. Following the completion of the acquisition, the director directly owned 6,298 shares in the company, valued at $716,019.62. This represents a 16.67% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 2.80% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Ranger Investment Management L.P. purchased a new stake in Mesa Laboratories in the second quarter worth approximately $17,321,000. Diamond Hill Capital Management LLC Investment Advisor bought a new position in shares of Mesa Laboratories during the 2nd quarter valued at $15,507,000. William Blair Investment Management LLC purchased a new position in shares of Mesa Laboratories in the 3rd quarter worth $16,934,000. Dimensional Fund Advisors LP boosted its stake in shares of Mesa Laboratories by 7.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 124,630 shares of the medical instruments supplier's stock worth $11,018,000 after buying an additional 8,267 shares during the last quarter. Finally, Wasatch Advisors LP boosted its stake in shares of Mesa Laboratories by 125.8% in the 2nd quarter. Wasatch Advisors LP now owns 115,668 shares of the medical instruments supplier's stock worth $11,515,000 after buying an additional 64,435 shares during the last quarter. 90.60% of the stock is owned by hedge funds and other institutional investors.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc. develops and manufactures instruments and consumable products used to monitor and control quality in life sciences and other regulated industries. Its offerings support activities such as sterilization and disinfection monitoring, laboratory testing, biopharmaceutical development, and equipment calibration. The company's products include biological and chemical indicators, data loggers, calibration instruments, and tools used in clinical genomics and bioprocessing. Customers use these products to help verify processes, measure conditions, and meet quality requirements.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.